Daiichi Sankyo Europe GmbH

Featured Stories

For the last ten years we as Daiichi Sankyo Europe have supported young graduates from the Ludwig-Maximilians-University in Munich (LMU). read more...

The new Daiichi Sankyo Group’s Value Report is now available! The report includes business facts & figures, information about Daiichi Sankyo’s growth potential, CSR activities and much more. read more...

Featured News

Date	Description
05/02/2019 Research	FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor	PDF
14/01/2019 Research	Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer	PDF
07/01/2019 Products	Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet	PDF
19/12/2018 Research	Daiichi Sankyo Initiates First Novel-Novel Combination Study of Two Investigational Agents within its AML Franchise in Patients with AML	PDF
18/12/2018 Research	Daiichi Sankyo Out-Licenses ROS1/NTRK Inhibitor DS-6051 to AnHeart Therapeutics	PDF
show all

Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

Support For Young Talents

Value Report 2018